References
[1] Jena MK, Sharma NR, Petitt M, Maulik D, Nayak NR. (2020). Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta. Biomolecules, 10. https://doi.org/10.3390/biom10060953.
[2] Gil-Acevedo LA, Ceballos G, Torres-Ramos YD. (2022). Foetal lipoprotein oxidation and preeclampsia. Lipids in Health and Disease, 21:51. https://doi.org/10.1186/s12944-022-01663-5.
[3] Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, McAuliffe F, da Silva Costa F, von Dadelszen P, McIntyre HD, Kihara AB, Di Renzo GC, Romero R, D'Alton M, Berghella V, Nicolaides KH, Hod M. (2019). The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. International Journal of Gynaecology and Obstetrics: The official organ of the International Federation of Gynaecology and Obstetrics, 145 Suppl 1:1-33. https://doi.org/10.1002/ijgo.12802.
[4] Armaly Z, Zaher M, Knaneh S, Abassi Z. (2019). Preeclampsia: Pathogenesis and Mechanisms Based Therapeutic Approaches. Harefuah, 158:742-747,
[5] Osol G, Ko NL, Mandalà M, (2017), Altered Endothelial Nitric Oxide Signaling as a Paradigm for Maternal Vascular Maladaptation in Preeclampsia. Current Hypertension Reports, 19:82. https://doi.org/10.1007/s11906-017-0774-6.
[6] Erez O, Romero R, Jung E, Chaemsaithong P, Bosco M, Suksai M, Gallo DM, Gotsch F. (2022). Preeclampsia and eclampsia: the conceptual evolution of a syndrome. American Journal of Obstetrics and Gynecology, 226:S786-s803. https://doi.org/10. 1016/j.ajog.2021.12.001.
[7] Xiong J, Jin X, Xu K, Wu B, Xu Y, Ruan D, He X. (2022). LncRNA-loc391533 is involved in the progression of preeclampsia through VEGF. Ginekologia polska. https://doi.org/10.5603/GP.a2022.0056.
[8] Bokuda K, Ichihara A (2023) Preeclampsia up to date-What's going on? Hypertension research: Official journal of the Japanese Society of Hypertension, 46:1900-1907. https://doi.org/10.1038/s41440-023-01323-w.
[9] Ngene NC, Moodley J. (2018). Role of angiogenic factors in the pathogenesis and management of pre-eclampsia. International Journal of Gynaecology and Obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 141:5-13. https://doi.org/10.1002/ijgo.12424.
[10] Lee NMW, Chaemsaithong P, Poon LC. (2024). Prediction of preeclampsia in asymptomatic women. Best practice & research Clinical Obstetrics & Gynaecology, 92:102436. https://doi.org/10.1016/j.bpobgyn.2023.102436.
[11] Parchem JG, Kanasaki K, Kanasaki M, Sugimoto H, Xie L, Hamano Y, Lee SB, Gattone VH, Parry S, Strauss JF, Garovic VD, McElrath TF, Lu KH, Sibai BM, LeBleu VS, Carmeliet P, Kalluri R. (2018). Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice. The Journal of Clinical Investigation, 128:5008-5017. https://doi.org/10.1172/jci99026.
[12] Zuo Q, Zou Y, Huang S, Wang T, Xu Y, Zhang T, Zhang M, Ge Z, Jiang Z. (2021). Aspirin reduces sFlt-1-mediated apoptosis of trophoblast cells in preeclampsia. Molecular Human Reproduction, 27. https://doi.org/10.1093/molehr/gaaa089.
[13] Wojcik M, Karouni F, Jindal S, Kapaya H. (2021). Implementing placental-growth-factor (PLGF) measurements in suspected pre-eclampsia—Challenges in clinical practice. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 266:157-162. https://doi.org/10.1016/j.ejogrb.2021.10.006.
[14] Hromadnikova I, Dvorakova L, Kotlabova K, Krofta L. (2019). The Prediction of Gestational Hypertension, Preeclampsia and Fetal Growth Restriction via the First Trimester Screening of Plasma Exosomal C19MC microRNAs. International Journal of Molecular Sciences, 20. https://doi.org/10.3390/ijms20122972.
[15] Savka RF, Mykolaiovych Berbets A, Mykhailovych Barbe A, Mykhailovych Yuzko O, Radu MR. (2023). Changes in concentrations of melatonin, PlGF, and cytokines in women with preeclampsia. Journal of Medicine and Life, 16:471-476. https://doi.org/10.25122/jml-2022-0283.
[16] Chang X, He Q, Wei M, Jia L, Wei Y, Bian Y, Duan T, Wang K (2023) Human umbilical cord mesenchymal stem cell derived exosomes (HUCMSC-exos) recovery soluble fms-like tyrosine kinase-1 (sFlt-1)-induced endothelial dysfunction in preeclampsia. European Journal of Medical Research, 28:277. https://doi.org/10.1186/s40001-023-01182-8.
[17] Huang X, Jia L, Jia Y, Xu X, Wang R, Wei M, Li H, Peng H, Wei Y, He Q, Wang K. (2023). sFlt-1-enriched exosomes induced endothelial cell dysfunction and a preeclampsia-like phenotype in mice. Cytokine, 166:156190. https://doi.org/10.1016/ j.cyto.2023.156190.
[18] Agrawal S, Cerdeira AS, Redman C, Vatish M. (2018). Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study. Hypertension (Dallas, Tex: 1979), 71:306-316. https://doi.org/10.1161/hypertensionaha.117.10182.
[19] Dröge LA, Perschel FH, Stütz N, Gafron A, Frank L, Busjahn A, Henrich W, Verlohren S. (2021). Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine: A Real-World Study. Hypertension (Dallas, Tex: 1979), 77:461-471. https://doi.org/10.1161/hypertensionaha.120.15146.
[20] Nóbrega L, Katz L, Lippo L, Amorim MM. (2022). Association of sFlt-1 and C-reactive protein with outcomes in severe preeclampsia: A cohort study. Medicine, 101. https://doi.org/10.1097/md.0000000000029059.
[21] Tanaka H, Nagahashi Y, Toriyabe K, Maki S, Takakura S, Enomoto N, Tanaka K, Shinji K, Ikeda T. (2022). sFlt-1 value predicts pregnancy prolongation periods from diagnosis in pregnant women diagnosed with early-onset preeclampsia. The Journal of Ma-ternal-Fetal & Neonatal Medicine: The Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet, 35:4196-4198. https://doi.org/10.1080/ 14767058.2020.1849093.